|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dusek L, Muzik J, Maluskova D, Májek O,
Pavlik T, Koptíková J, Melichar B, Büchler T, Fínek J, Cibula D, et
al: Cancer incidence and mortality in the Czech Republic. Klin
Onkol. 27:406–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new american joint committee on
cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendrick JP and Hartl FU: Molecular
chaperone functions of heat-shock proteins. Annu Rev Biochem.
62:349–384. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pockley AG: Heat shock proteins,
inflammation, and cardiovascular disease. Circulation.
105:1012–1017. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Henderson B, Fares MA and Lund PA:
Chaperonin 60: A paradoxical, evolutionarily conserved protein
family with multiple moonlighting functions. Biol Rev Camb Philos
Soc. 88:955–987. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marino Gammazza A, Rizzo M, Citarrella R,
Rappa F, Campanella C, Bucchieri F, Patti A, Nikolic D, Cabibi D,
Amico G, et al: Elevated blood Hsp60, its structural similarities
and cross-reactivity with thyroid molecules, and its presence on
the plasma membrane of oncocytes point to the chaperonin as an
immunopathogenic factor in hashimoto's thyroiditis. Cell Stress
Chaperones. 19:343–353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomasello G, Rodolico V, Zerilli M,
Martorana A, Bucchieri F, Pitruzzella A, Marino Gammazza A, David
S, Rappa F, Zummo G, et al: Changes in immunohistochemical levels
and subcellular localization after therapy and correlation and
colocalization with CD68 suggest a pathogenetic role of Hsp60 in
ulcerative colitis. Appl Immunohistochem Mol Morphol. 19:552–561.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cappello F, Caramori G, Campanella C,
Vicari C, Gnemmi I, Zanini A, Spanevello A, Capelli A, La Rocca G,
Anzalone R, et al: Convergent sets of data from in vivo and in
vitro methods point to an active role of Hsp60 in chronic
obstructive pulmonary disease pathogenesis. PLoS One. 6:e282002011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Czarnecka AM, Campanella C, Zummo G and
Cappello F: Mitochondrial chaperones in cancer: From molecular
biology to clinical diagnostics. Cancer Biol Ther. 5:714–720. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cappello F, Bellafiore M, Palma A, David
S, Marcianò V, Bartolotta T, Sciumè C, Modica G, Farina F, Zummo G
and Bucchieri F: 60KDa chaperonin (Hsp60) is over-expressed during
colorectal carcinogenesis. Eur J Histochem. 47:105–110. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Y, Wu Y, Mou Z, Li W, Zou L, Fu T,
Zhang A, Xiang D, Xiao H and Wang X: Proteomics-based
identification of HSP60 as a tumor-associated antigen in colorectal
cancer. Proteomics Clin Appl. 1:336–342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bini L, Magi B, Marzocchi B, Arcuri F,
Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini
V, et al: Protein expression profiles in human breast ductal
carcinoma and histologically normal issue. Electrophoresis.
18:2832–2841. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Castilla C, Congregado B, Conde JM, Medina
R, Torrubia FJ, Japón MA and Sáez C: Immunohistochemical expression
of Hsp60 correlates with tumor progression and hormone resistance
in prostate cancer. Urology. 76:1017.e1–e6. 2010. View Article : Google Scholar
|
|
15
|
Cappello F, David S, Rappa F, Bucchieri F,
Marasà L, Bartolotta TE, Farina F and Zummo G: The expression of
HSP60 and HSP10 in large bowel carcinomas with lymph node
metastase. BMC Cancer. 5:1392005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamelin C, Cornut E, Poirier F, Sylvie
Pons S, Beaulieu C, Charrier JP, Haïdous H, Cotte E, Lambert C,
Piard F, et al: Identification and verification of heat shock
protein 60 as a potential serum marker for colorectal cancer. FEBS
J. 278:4845–4859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johansen JS, Schultz NA and Jensen BV:
Plasma YKL-40: A potential new cancer biomarker? Future Oncol.
5:1065–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johansen JS, Høyer PE, Larsen LA, Price PA
and Møllgård K: YKL-40 protein expression in the early developing
human musculoskeletal system. J Histochem Cytochem. 55:1213–1228.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brøchner CB, Johansen JS, Larsen LA, Bak
M, Mikkelsen HB, Byskov AG, Andersen CY and Møllgård K: YKL-40 is
differentially expressed in human embryonic stem cells and in cell
progeny of the three germ layers. J Histochem Cytochem. 60:188–204.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faibish M, Francescone R, Bentley B, Yan W
and Shao R: A YKL-40 neutralizing antibody blocks tumor
angiogenesis and progression: A potential therapeutic agent in
cancers. Mol Cancer Ther. 10:742–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shao R: YKL-40 acts as an angiogenic
factor to promote tumor angiogenesis. Front Physiol. 4:1222013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee CG, Da Silva C, Dela Cruz CS, Ahangari
F, Ma B, Kang MJ, He CH, Takyar S and Elias JA: Role of chitin and
chitinase/chitinase-like proteins in inflammation, tissue
remodelling, and injury. Annu Rev Physiol 2011;. 73:479–501. 2011.
View Article : Google Scholar
|
|
23
|
Kawada M, Seno H, Kanada K, Nakanishi Y,
Akitake R, Komekado H, Kawada K, Sakai Y, Mizoguchi E and Chiba T:
Chitinase 3-like-1 promotes macrophage recruitment and angiogenesis
in colorectal cancer. Oncogene. 31:3111–3123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eurich K, Segawa M, Toei-Shimizu S and
Mizoguchi E: Potential role of chitinase 3-like-1 in
inflammation-associated carcinogenic changes of epithelial cells.
World J Gastroenterol. 15:5249–5259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen CC, Llado V, Eurich K, Tran HT and
Mizoguchi E: Carbohydrate-binding motif in chitinase 3-like 1
(CHI3L1/YKL-40) specifically activates akt signaling pathway in
colonic epithelial cells. Clin Immunol. 140:268–275. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee CG, Hartl D, Lee GR, Koller B,
Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, et
al: Role of breast regression protein 39 (BRP-39)/Chitinase
3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J
Exp Med. 206:1149–1166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johansen JS, Christensen IJ, Jørgensen LN,
Olsen J, Rahr HB, Nielsen KT, Lurberg S, Brünner N and Nielsen HJ:
Serum YKL-40 in risk assessment for colorectal cancer: A
prospective study of 4,496 subjects at risk of colorectal cancer.
Cancer Epidemiol Biomarkers Prev. 24:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johansen JS, Bojesen SE, Mylin AK,
Frikke-Schmidt R, Price PA and Nordestgaard BG: Elevated plasma
YKL-40 predicts increased risk of gastrointestinal cancer and
decreased survival after any cancer diagnosis in the general
population. J Clin Oncol. 27:572–578. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johansen JS, Bojesen SE, Tybjærg-Hansen A,
Mylin AK, Price PA and Nordestgaard BG: Plasma YKL-40 and total and
disease-specific mortality in the general population. Clin Chem.
56:1580–1591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cintin C, Johansen JS, Christensen IJ,
Price PA, Sørensen S and Nielsen HJ: High serum YKL-40 level after
surgery for colorectal carcinoma is related to short survival.
Cancer. 95:267–274. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cintin C, Johansen JS, Christensen IJ,
Price PA, Sørensen S and Nielsen HJ: Serum YKL-40 and colorectal
cancer. Br J Cancer. 79:1494–1499. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Zhang Y, Zhu Z, Ha M and Wang Y:
Elevated pretreatment serum concentration of YKL-40: An independent
prognostic biomarker for poor survival in patients with colorectal
cancer. Med Oncol. 31:852014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Clemmons DR: Insulin-like growth factor
binding proteins and their role in controlling IGF actions.
Cytokine Growth Factor Rev. 8:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pollak MN, Schernhammer ES and Hankinson
E: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schütt BS, Langkamp M, Rauschnabel U,
Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like
growth factor binding protein-2 in tumor cells. J Mol Endocrinol.
32:859–868. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jogie-Brahim S, Feldman D and Oh Y:
Unraveling insulin-like growth factor binding protein-3 actions in
human disease. Endocr Rev. 30:417–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liou JM, Shun CT, Liang JT, Chiu HM, Chen
MJ, Chen CC, Wang HP, Wu MS and Lin JT: Plasma insulin-like growth
factor-binding protein-2 levels as diagnostic and prognostic
biomarkers of colorectal cancer. J Clin Endocrinol Metab.
95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schoen RE, Tangen CM, Kuller LH, Burke GL,
Cushman M, Tracy RP, Dobs A and Savage PJ: Increased blood glucose
and insulin, body size, and incident colorectal cancer. J Natl
Cancer Inst. 91:1147–1154. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hung CS, Huang CY, Lee CH, Chen WY, Huang
MT, Wei PL and Chang YJ: IGFBP2 plays an important role in heat
shock protein 27-mediated cancer progression and metastasis.
Oncotarget. 8:54978–54992. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cohen P, Peehl DM, Stamey TA, Wilson KF,
Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like
growth factor-binding protein-2 in the serum of prostate cancer
patients. J Clin Endocrinol Metab. 76:1031–1035. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Renehan AG, Jones J, Potten CS, Shalet SM
and O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II
and IGF binding protein-2 in patients with colorectal cancer. Br J
Cancer. 83:1344–1350. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kushlinskii NE, Gershtein ES, Nikolaev AA,
Delektorskaya VV, Korotkova EA, Dvorova EA and Kostyleva OI:
Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP),
and vascular endothelial growth factor (VEGF) in blood serum of
patients with colorectal cancer. Bull Exp Biol Med. 156:684–688.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee DY, Kim SJ and Lee YC: Serum
insulin-like growth factor (IGF)-I and IGF-binding proteins in lung
cancer patients. J Korean Med Sci. 14:401–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vocka M, Langer D, Petrtyl J, Vockova P,
Hanus T, Kalousova M, Zima T and Petruzelka L: Trefoil factor
family (TFF) proteins as potential serum biomarkers in patients
with metastatic colorectal cancer. Neoplasma. 62:470–477. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rodolico V, Tomasello G, Zerilli M,
Martorana A, Pitruzzella A, Gammazza AM, David S, Zummo G, Damiani
P, Accomando S, et al: Hsp60 and Hsp10 increase in colon mucosa of
Crohn's disease and ulcerative colitis. Cell Stress Chaperones.
15:877–884. 2015. View Article : Google Scholar
|
